# Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

> **NCT05516498** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 205 (actual)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)
- **DRUG:** Part A: zibotentan (dose B) + dapagliflozin
- **DRUG:** Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)
- **DRUG:** Part B: placebo (matching zibotentan capsule) + dapagliflozin
- **DRUG:** Part B: zibotentan (dose A) + dapagliflozin
- **DRUG:** Part B: zibotentan (dose B) + dapagliflozin
- **DRUG:** Part B: zibotentan (dose C) + dapagliflozin

## Key facts

- **NCT ID:** NCT05516498
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-31
- **Primary completion:** 2025-05-22
- **Final completion:** 2025-07-17
- **Target enrollment:** 205 (ACTUAL)
- **Why stopped:** The study was ended earlier than planned due to a sponsor decision.
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05516498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05516498, "Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05516498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*